Pfizer (PFE) Acquires Emergen-C Maker Alacer Corp
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $24.17 -0.33%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.1%
Revenue Growth %: -1.9%
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.
Financial terms of the transaction were not disclosed. Lazard acted as financial advisor to Pfizer, and DLA Piper LLP (U.S.) acted as legal advisor to Pfizer, in connection with the acquisition. Houlihan Lokey acted as financial advisor to the owners of Alacer Corp., and Rutan & Tucker LLP acted as legal advisor to the owners of Alacer Corp., in connection with the transaction.
Financial terms of the transaction were not disclosed. Lazard acted as financial advisor to Pfizer, and DLA Piper LLP (U.S.) acted as legal advisor to Pfizer, in connection with the acquisition. Houlihan Lokey acted as financial advisor to the owners of Alacer Corp., and Rutan & Tucker LLP acted as legal advisor to the owners of Alacer Corp., in connection with the transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Pfizer (PFE) to Hold
- NSA sets July 22 closing for Public Storage acquisition
- Activist Toms Is Said To Want Devon Energy To Shed Assets - Bloomberg
Create E-mail Alert Related Categories
Mergers and AcquisitionsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
